KBY Biotech Indexv0.0.34
Search
← Pipeline|Ribotuximab

Ribotuximab

Phase 1
REM-8288
By Remix Ther
Source: Trial-derived·Trials: 2
Modality
ADC
MOA
PD-L1i
Target
MALT1
Pathway
T-cell
WMCSU
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Nov 2028
Phase 1Current
NCT08966538
1,679 pts·WM
2024-08→2027-07·Active
NCT05911049
2,128 pts·WM
2025-08→2028-11·Active
3,807 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-07-271.3y awayInterim· WM
2028-11-062.6y awayInterim· WM
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Active
P1
Active
Catalysts
Interim
2027-07-27 · 1.3y away
WM
Interim
2028-11-06 · 2.6y away
WM
Active|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT08966538Phase 1WMActive1679Safety
NCT05911049Phase 1WMActive2128UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-1085PfizerPreclinicalFXIaPD-L1i
JNJ-8232Johnson & JohnsonNDA/BLAMALT1SGLT2i
RilulemzoparlimabNovartisPhase 2/3KRASG12DPD-L1i
BMY-7975Bristol-Myers SquibbPhase 1MALT1WRNi
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
GSK-6516GSKPhase 1/2MALT1PARPi
NirafutibatinibBayerPhase 2WRNPD-L1i
MotainavolisibAmgenNDA/BLACD47PD-L1i
BNT-8090BioNTechPhase 2AuroraAPD-L1i
BII-5240BiogenPhase 2/3MALT1HPK1i